Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07664007 | Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. | completed | N/A | 18 | Instituto de Investigación Sanitaria AragónOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04483726 | Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)(DIPLOMA) | completed | N/A | 9 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT04457284 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | completed | Phase 1 | 39 | AdaptimmuneINDUSTRY | 4 | Jun 17, 2026 | clinicaltrials |
| NCT00554372 | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | completed | Phase 2 | 30 | Jennerex BiotherapeuticsINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT03269526 | BATs Treatment for Pancreatic Cancer, Phase Ib/II | completed | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03307408 | Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease(CHALNA) | completed | — | 180 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04829383 | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma(AB7) | completed | Phase 2 | 6 | Howard S HochsterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03158818 | Chronic Hepatitis B Virus Infection in Zambia(HUTCH) | completed | — | 326 | University of Alabama at BirminghamOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04774198 | Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy | completed | — | 58 | Rigshospitalet, DenmarkOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05545293 | Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers | completed | — | 100 | West China HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05630183 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | completed | Phase 2 | 81 | Agenus Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03311152 | Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis(SEPT9_CROSS) | completed | N/A | 639 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05773105 | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | completed | Phase 1 / Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04739202 | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)(IMMUNOGAST) | completed | Phase 2 | 54 | Hospices Civils de LyonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone(PHOCUS) | completed | Phase 3 | 459 | SillaJen, Inc.INDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | completed | Phase 3 | 203 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04954339 | DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab(DYNAMIC) | completed | Phase 2 | 40 | Tae Won KimOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619937 | Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma | completed | Phase 2 | 31 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621536 | Diagnostic Accuracy of Eus Fnb in Difficult to Reach Lesions | completed | — | 131 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05667064 | Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study | completed | — | 1,200 | AstraZenecaINDUSTRY | 0 | Jun 1, 2026 | clinicaltrials |
| NCT04183218 | Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes | completed | — | 24 | Mayo ClinicOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT05955833 | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study(HER Image) | completed | N/A | 6 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06266143 | A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 71 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT05874934 | Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String(CHORDA-II-p) | completed | N/A | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04572711 | Prospective Evaluation of Biliary Tissue Sampling With ERCP | completed | — | 327 | Mayo ClinicOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04687969 | Multimodal Machine Learning Characterization of Solid Tumors | completed | — | 50 | Ciprian Catana, MD, PhDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05099848 | A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma | completed | Phase 2 | 21 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02890355 | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT07598331 | Contrast-Enhanced Ultrasound for Early Assessment of Microwave Ablation in HCC(SBS-CEUS) | completed | N/A | 106 | The First Hospital of Jilin UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04984733 | Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer(ELEVATE) | completed | Phase 2 | 13 | University of SouthamptonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06626087 | A Prototype AI Algorithm Versus Liver Imaging Reporting and Data System (LI-RADS) Criteria in Diagnosing HCC on CT(Hepatocellular) | completed | N/A | 300 | The University of Hong KongOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02305459 | CIRSE Registry for SIR-Spheres Therapy(CIRT) | completed | — | 1,051 | Cardiovascular and Interventional Radiological Society of EuropeOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03033446 | Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma | completed | Phase 2 | 40 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03086096 | CIRSE Registry for LifePearl Microspheres(CIREL) | completed | — | 152 | Cardiovascular and Interventional Radiological Society of EuropeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03415854 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)(NABPLAGEMD) | completed | Phase 2 | 34 | HonorHealth Research InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06881446 | Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions | completed | — | 2,651 | Zhongda HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03851237 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | completed | Phase 1 | 69 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04736485 | Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)(GASPAR) | completed | Phase 2 | 67 | Centre Francois BaclesseOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials